Since randomized clinical trial in 1990 of a positive therapeutic effect of the H2R antagonist famotidine on the negative symptoms in schizophrenia, the open-label study also indicated the effective role of the H2R antagonist ranitidine in negative symptoms [78,79]. Here, HRH2 is linked to schizophrenia.